These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1591301)

  • 21. Purging marrow or peripheral blood stem cells for autografting.
    Hammert LC; Ball ED
    Curr Opin Hematol; 1997 Nov; 4(6):423-8. PubMed ID: 9359000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow processing for transplantation.
    Areman EM; Sacher RA
    Transfus Med Rev; 1991 Jul; 5(3):214-27. PubMed ID: 1687956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
    Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies.
    Uckun FM; Myers DE
    J Hematother; 1993; 2(2):155-63. PubMed ID: 7921971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous graft engineering.
    Gulati SC
    J Hematother; 1992; 1(2):183-90. PubMed ID: 1365026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell depletion and allogeneic bone marrow transplantation.
    O'Reilly RJ
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):20-6. PubMed ID: 1615341
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of amifostine in bone marrow purging.
    Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing reconstitution by bone marrow transplantation.
    van Bekkum DW; Wielenga JJ; van Gils F; Wagemaker G
    Prog Clin Biol Res; 1990; 352():479-91. PubMed ID: 1698302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.
    Fricke S; Rothe K; Hilger N; Ackermann M; Oelkrug C; Fricke C; Schönfelder U; Niederwieser D; Emmrich F; Sack U
    Cytometry A; 2012 Jun; 81(6):476-88. PubMed ID: 22522779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning.
    Jaime-Pérez JC; Villarreal-Villarreal CD; Méndez-Ramírez N; Vázquez-Garza E; Salazar-Riojas R; Gómez-Almaguer D
    Blood Cells Mol Dis; 2016 May; 58():52-6. PubMed ID: 27067489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
    Rowley SD; Piantadosi S; Marcellus DC; Jones RJ; Davidson NE; Davis JM; Kennedy J; Wiley JM; Wingard JR; Yeager AM
    Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation.
    Cayeux SJ; Beverley PC; Schulz R; Dörken B
    Bone Marrow Transplant; 1993 Dec; 12(6):603-8. PubMed ID: 7907905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of photodynamic therapy in bone marrow purging.
    Mulroney CM; Glück S; Ho AD
    Semin Oncol; 1994 Dec; 21(6 Suppl 15):24-7. PubMed ID: 7992104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prompt haemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukaemia.
    Herrmann RP; O'Reilly J; Meyer BF; Lazzaro G
    Bone Marrow Transplant; 1992 Sep; 10(3):293-5. PubMed ID: 1358379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Autologous bone marrow transplantation for CML].
    Nagamura F; Nagamura-Inoue T
    Nihon Rinsho; 2001 Dec; 59(12):2369-74. PubMed ID: 11766341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purging with 4-hydroperoxycyclophosphamide.
    Jones RJ
    J Hematother; 1992; 1(4):343-8. PubMed ID: 1345676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Indications for bone marrow and peripheral stem cell transplantation in malignant hematological diseases].
    Gratwohl A
    Ther Umsch; 1996 Feb; 53(2):152-7. PubMed ID: 8629266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.